Increased expression of ICAM-1 and VCAM-1 in the skin after administration of the first dose of OKT3.
ten Berge
R J
RJ
University of Amsterdam, Department of Internal Medicine, The Netherlands.
Buysmann
S
S
van Diepen
F N
FN
Surachno
S
S
Pals
S T
ST
D000328:Adult; D000911:Antibodies, Monoclonal; D001706:Biopsy; D005260:Female; D006084:Graft Rejection / Q000276:immunology* / Q000473:pathology / Q000628:therapy*; D006801:Humans; D007166:Immunosuppressive Agents / Q000627:therapeutic use*; D018799:Intercellular Adhesion Molecule-1 / Q000096:biosynthesis*; D016030:Kidney Transplantation / Q000276:immunology*; D008297:Male; D008875:Middle Aged; D016853:Muromonab-CD3 / Q000627:therapeutic use*; D012867:Skin / Q000276:immunology* / Q000473:pathology; D013997:Time Factors; D019010:Vascular Cell Adhesion Molecule-1 / Q000096:biosynthesis*
D000911:Antibodies, Monoclonal; D007166:Immunosuppressive Agents; D016853:Muromonab-CD3; D019010:Vascular Cell Adhesion Molecule-1; D018799:Intercellular Adhesion Molecule-1